Chinese University of Hong Kong-Prince of Wales Hospital

Shatin, Hong Kong OX1 3UJ

0 studies enrolling now · 8 studies all time

What they study most

Distal Urethral Cancer, Epstein-Barr Virus Infection, Head and Neck Cancer, Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Metastatic Nasopharyngeal Nonkeratinizing Carcinoma, Metastatic Nasopharyngeal Undifferentiated Carcinoma, Nasopharyngeal Nonkeratinizing Carcinoma, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma

Studies at this site

• Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA — Running, not enrolling
• RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer — Running, not enrolling
• Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer — Stopped early
• Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer — Completed
• Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer — Completed
• Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer — Completed
• Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy — Completed
• Pazopanib in Treating Patients With Metastatic Urothelial Cancer — Completed